Regulatory PathRegulatory requirements compared

Active substances

Naphazoline + Pheniramine

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
NAPHCON-A EYE DROPS3,0.025 %,%Eye drops · Ophthalmic use1 Dropper ContainerSAR 17.25NCE · OTCALCON N.V.Valid
Indications — CHI Daman Drug Formulary

ALLERGIC CONJUCTIVITIS (AC); ALLERGIC RHINITIS; ALLERGIC RHINITIS-ALLERGIC RHINO-CONJUNCTIVITIS; VIRAL CONJUNCTIVITS, HERPESVIRAL KERATITIS, HERPESVIRAL CONJUNCTIVITIS, VARICELLA KERATITIS, ZOSTER CONJUNCTIVITIS, ZOSTER KERATITIS, MEASLES KERATITIS AND KERATOCONJUNCTIVITIS, VIRAL CONJUNCTIVITIS, KERATITIS

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
OPCON-A0.02675%;0.315%solution/drops · ophthalmicBAUSCH AND LOMBOver-the-counter8 Jun 1994
NAPHCON-A0.025%;0.3%solution/drops · ophthalmicALCONOver-the-counter8 Jun 1994
VISINE0.025%;0.3%solution/drops · ophthalmicKENVUE BRANDSOver-the-counter31 Jan 1996
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE0.02675%;0.315%solution/drops · ophthalmicALTAIRE PHARMS INCOver-the-counter27 Sep 2010
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE0.025%;0.3%solution/drops · ophthalmicRISINGOver-the-counter24 Jan 2013

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
NAPHCON A004814080.025 %; 0.3 %SOLUTION · OPHTHALMICALCON CANADA INC
SOOTHE ALLERGY007507940.315 % / W/V; 0.02675 % / W/VDROPS · OPHTHALMICBAUSCH & LOMB INC
VISINE FOR ALLERGY WITH ANTIHISTAMINE022427640.025 % / W/V; 0.3 % / W/VDROPS · OPHTHALMICJOHNSON & JOHNSON INC

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACNAPHCON-A EYE DROPS$0.55744per ML23 Sep 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.